Altamash Shaikh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Altamash Shaikh has a total of 81 co-authors. Here are the top co-authors by number of shared publications:
- Abhamoni Baro
Gauhati Medical College and Hospital, Guwahati, India
1 shared publication - Abhishek Katakwar
Asian Institute of Gastroenterology, Hyderabad, India
1 shared publication - Ambika Gopalakrishnan Unnikrishnan
Chellaram Diabetes Institute, Pune, India
1 shared publication - Ambrish Mithal
Institute of Endocrinology and Diabetes, Max Healthcare, New Delhi, India
1 shared publication - Ana Soraya Palmira Dos Remedios Monteiro
Goa Medical College, Bambolim, India
1 shared publication - Aparna Govil Bhasker
Saifee Hospital, Mumbai, India
1 shared publication
Latest Publications
- 3 August 2026
- Published by Springer Nature in Obesity Surgery
- Vol. 36 (9) , 4961-4982
Expert Consensus on Obesity Management Protocols – A Joint Position Statement by Obesity and Metabolic Surgery Society of India (OSSI) and Endocrine Society of India (ESI)
- 3 August 2026
- Published by Springer Nature in Obesity Surgery
- Vol. 36 (9) , 4961-4982
Expert Consensus on Obesity Management Protocols – A Joint Position Statement by Obesity and Metabolic Surgery Society of India (OSSI) and Endocrine Society of India (ESI)
- Open Access
- 19 September 2017
- Published by Springer Nature in Diabetes Therapy
- Vol. 8 (5) , 981-989
A Practical Approach to Hypertension Management in Diabetes
Hypertension is one of the most important comorbidities of diabetes, contributing significantly to death and disability and leads to macrovascular and microvascular complications. When assessing the medical priorities for patients with diabetes, treating hypertension should be a primary consideration. Practical approaches to hypertension in diabetes, including individualized targets are discussed, as per stage and complication of diabetes, according to current studies and guidelines. Angiotensin converting enzyme inhibitors (ACEI)/angiotensin receptor blockers (ARBs) are the most effective drugs for treating hypertension in diabetes, in the absence of contraindications. Calcium antagonists or diuretics are acceptable as second-line agents. Once the target is achieved, antihypertensive drugs should be continued. Newer antidiabetes medications such as sodium glucose cotransporter-2 inhibitors (SGLT2i), glucagon-like peptide-1 receptor agonists (GLP1-RA), and dipeptidyl peptidase-4 inhibitors (DPP4i) have antihypertensive properties and may assist in treatment decision-making.
- 19 September 2017
- Published by Springer Nature in Diabetes Therapy
- Vol. 8 (5) , 981-989
Open AccessA Practical Approach to Hypertension Management in Diabetes
Hypertension is one of the most important comorbidities of diabetes, contributing significantly to death and disability and leads to macrovascular and microvascular complications. When assessing the medical priorities for patients with diabetes, treating hypertension should be a primary consideration. Practical approaches to hypertension in diabetes, including individualized targets are discussed, as per stage and complication of diabetes, according to current studies and guidelines. Angiotensin converting enzyme inhibitors (ACEI)/angiotensin receptor blockers (ARBs) are the most effective drugs for treating hypertension in diabetes, in the absence of contraindications. Calcium antagonists or diuretics are acceptable as second-line agents. Once the target is achieved, antihypertensive drugs should be continued. Newer antidiabetes medications such as sodium glucose cotransporter-2 inhibitors (SGLT2i), glucagon-like peptide-1 receptor agonists (GLP1-RA), and dipeptidyl peptidase-4 inhibitors (DPP4i) have antihypertensive properties and may assist in treatment decision-making.
- 13 September 2017
- Published by Springer Nature in Diabetologia
- Vol. 60 (12) , 2536-2537
SGLT2 inhibitors and cancer: why further evidence is required.
- 13 September 2017
- Published by Springer Nature in Diabetologia
- Vol. 60 (12) , 2536-2537
SGLT2 inhibitors and cancer: why further evidence is required.
- Open Access
- 1 January 2017
- Published by Medknow in Indian Journal of Endocrinology and Metabolism
- Vol. 21 (6) , 928-929
Sulfonylureas: Scoring beyond START STUDY
Indian J Endocr Metab, Official publication of Endocrine Society of India,India
- 1 January 2017
- Published by Medknow in Indian Journal of Endocrinology and Metabolism
- Vol. 21 (6) , 928-929
Open AccessSulfonylureas: Scoring beyond START STUDY
Indian J Endocr Metab, Official publication of Endocrine Society of India,India
- Open Access
- 1 January 2013
- Published by Medknow in Indian Journal of Endocrinology and Metabolism
- Vol. 17 (9) , 685-7
Seedless orchids: Issues in the anorchid adult
Disorders of sexual differentiation (DSD) are among the challenging problems in the field of endocrinology. When presenting late in an adult the therapeutic as well as diagnostic issues may be different and difficult. Bilateral anorchia is rare. The desire of future parenting is a real challenge when such patients ask for their own biological generations. This case depicts the late presentation of DSD in an anorchid adult and the management issues.
- 1 January 2013
- Published by Medknow in Indian Journal of Endocrinology and Metabolism
- Vol. 17 (9) , 685-7
Open AccessSeedless orchids: Issues in the anorchid adult
Disorders of sexual differentiation (DSD) are among the challenging problems in the field of endocrinology. When presenting late in an adult the therapeutic as well as diagnostic issues may be different and difficult. Bilateral anorchia is rare. The desire of future parenting is a real challenge when such patients ask for their own biological generations. This case depicts the late presentation of DSD in an anorchid adult and the management issues.
- Open Access
- 1 January 2013
- Published by Medknow in Indian Journal of Endocrinology and Metabolism
- Vol. 17 (7) , 292-4
Family therapy
Another major force not letting us succeed in the treatment of diabetes remains right inside the patients home, their family members. Hence, it is important to know the perception of the close family members about this simple and strong tool in diabetes, 'insulin'. The drug is nearing its century, it has not fully being accepted gracefully even in todays electronic savvy society. So, we need to strongly discover the reason for its non-acceptance, while trials are out inventing new drugs. One vital thing that can change this attitude is increasing the understanding of this drug, insulin in depth to close people around the patient, the 'family'. Underestimating family's perception about disease and treatment for diabetes is detrimental to both diseased and the doctor. This consists of a biopsychosocial model; biological, psychological and social factors. Family forms the most important part of it. The strategies in family therapy include psychodynamic, structural, strategic, and cognitive-behavioral component. Diabetes has and will continue to rise, so will be the treatment options. From the clinicians side its to fix fasting first but from patients its fix family first. Family therapy demonstrates the importance of insulin initiation and maintenance in insulin naive patients, and continuation for others. The specific needs of such patients and their impact on family life are met with family therapy. Who needs family therapy? Benefits of family therapy and a case based approach is covered.
- 1 January 2013
- Published by Medknow in Indian Journal of Endocrinology and Metabolism
- Vol. 17 (7) , 292-4
Open AccessFamily therapy
Another major force not letting us succeed in the treatment of diabetes remains right inside the patients home, their family members. Hence, it is important to know the perception of the close family members about this simple and strong tool in diabetes, 'insulin'. The drug is nearing its century, it has not fully being accepted gracefully even in todays electronic savvy society. So, we need to strongly discover the reason for its non-acceptance, while trials are out inventing new drugs. One vital thing that can change this attitude is increasing the understanding of this drug, insulin in depth to close people around the patient, the 'family'. Underestimating family's perception about disease and treatment for diabetes is detrimental to both diseased and the doctor. This consists of a biopsychosocial model; biological, psychological and social factors. Family forms the most important part of it. The strategies in family therapy include psychodynamic, structural, strategic, and cognitive-behavioral component. Diabetes has and will continue to rise, so will be the treatment options. From the clinicians side its to fix fasting first but from patients its fix family first. Family therapy demonstrates the importance of insulin initiation and maintenance in insulin naive patients, and continuation for others. The specific needs of such patients and their impact on family life are met with family therapy. Who needs family therapy? Benefits of family therapy and a case based approach is covered.